Literature DB >> 11567218

Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C.

H Fontaine1, B Nalpas, B Poulet, F Carnot, H Zylberberg, C Brechot, S Pol.   

Abstract

To analyze the spontaneous pathologic progression of chronic hepatitis C, we analyzed the histopathologic semiquantitative scores (Metavir and Knodell) of sequential liver biopsies performed in untreated hepatitis C virus (HCV)-infected patients. Subjects included 35 men and 41 women, with a mean age of 41 +/- 12 years, a duration of HCV infection of 11 +/- 5 years, and an interval between liver biopsies of 3.7 +/- 2.5 years. Results obtained using the Knodell score and the Metavir score were similar. At the first biopsy, 78.9% of patients had a low activity score (A0-A1) and 82.9% had a low fibrosis score (F0-F2). At the second biopsy, the activity decreased in 9.2%, was unchanged in 72.4%, and increased in 18.5%. An increase in activity was more frequently observed in patients infected with genotype 1 (28.9%) than with others (7.7%; P =.04); the yearly progression of activity was significantly higher in patients with a low rather than high initial activity score (0.11 v -0.02; P <.01). An increase in fibrosis was noted in 13.3% of those with a low and 43.8% of those with a high initial activity score (P <.01), with a highest rate of yearly fibrosis progression (0.12 U). In multivariate analysis, only a high activity score was significantly associated with an increased risk of fibrosis progression (relative risk, 25.5; 95% confidence interval, 2.7 to 238; P =.004). Spontaneous chronic hepatitis C evolution is worsening in only 20% of patients. Fibrosis progression is significantly associated with the necroinflammatory activity suggesting that this factor should be regarded as a major clue for deciding therapy. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567218     DOI: 10.1053/hupa.2001.28228

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C.

Authors:  Yumi Kobayashi; Yasunori Kawaguchi; Toshihiko Mizuta; Takuya Kuwashiro; Satoshi Oeda; Noriko Oza; Hirokazu Takahashi; Shinji Iwane; Yuichiro Eguchi; Keizo Anzai; Iwata Ozaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2010-11-03       Impact factor: 7.527

2.  Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?

Authors:  Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 3.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

4.  Pathogenesis of systemic Mycobacterium avium infection in pigs through histological analysis of hepatic lesions.

Authors:  Kenji Hibiya; Kimiko Utsunomiya; Takashi Yoshida; Satoshi Toma; Futoshi Higa; Masao Tateyama; Jiro Fujita
Journal:  Can J Vet Res       Date:  2010-10       Impact factor: 1.310

5.  Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease.

Authors:  V Paradis; I Bièche; D Dargère; D Cazals-Hatem; I Laurendeau; V Saada; J Belghiti; A Bezeaud; M Vidaud; P Bedossa; D-C Valla
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

Review 6.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Authors:  Elham Shirvani-Dastgerdi; Robert E Schwartz; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2016-08-06       Impact factor: 7.090

7.  Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Authors:  Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

8.  Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels.

Authors:  Akiko Fujiwara; Kohsaku Sakaguchi; Shinichi Fujioka; Yoshiaki Iwasaki; Tomonori Senoh; Mamoru Nishimura; Masako Terao; Yasushi Shiratori
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

9.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 10.  Fibrosis progression in chronic hepatitis C virus infection.

Authors:  G W McCaughan; J George
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.